Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TLSA |
---|---|---|
09:32 ET | 3854 | 1.03 |
09:34 ET | 2501 | 1.025 |
09:36 ET | 15700 | 0.98 |
09:38 ET | 1240 | 1 |
09:43 ET | 1386 | 0.985 |
09:45 ET | 149 | 1 |
09:54 ET | 640 | 0.9925 |
09:56 ET | 295 | 0.985 |
09:57 ET | 6000 | 1 |
10:06 ET | 200 | 0.9925 |
10:08 ET | 200 | 1 |
10:15 ET | 100 | 0.9851 |
10:19 ET | 1000 | 0.988825 |
10:26 ET | 14989 | 0.99 |
10:28 ET | 500 | 1 |
10:30 ET | 200 | 1 |
10:32 ET | 1200 | 0.9999 |
10:35 ET | 5807 | 1 |
10:37 ET | 115 | 0.99995 |
10:39 ET | 3050 | 1.0199 |
10:50 ET | 5000 | 1.03 |
10:55 ET | 100 | 1.0114 |
11:04 ET | 11000 | 1.02 |
11:09 ET | 10000 | 1.02 |
11:11 ET | 1300 | 1.0199 |
11:24 ET | 100 | 1.01 |
11:26 ET | 100 | 1.015 |
11:27 ET | 380 | 1.0113 |
11:33 ET | 1000 | 1.015 |
11:40 ET | 108 | 1.02 |
11:47 ET | 960 | 1.0101 |
12:00 ET | 100 | 1.02 |
12:14 ET | 100 | 1.0187 |
12:21 ET | 400 | 1.01 |
12:32 ET | 4036 | 1.0194 |
12:36 ET | 1100 | 1.015 |
12:41 ET | 100 | 1.01 |
12:43 ET | 100 | 1.0101 |
12:45 ET | 500 | 1.0109 |
12:48 ET | 100 | 1.0187 |
12:57 ET | 100 | 1.015 |
01:03 ET | 1500 | 1.0108 |
01:10 ET | 480 | 1.011 |
01:21 ET | 2692 | 1.01 |
01:26 ET | 400 | 1.015 |
01:30 ET | 100 | 1.01 |
01:33 ET | 200 | 1.01 |
01:35 ET | 348 | 1.01 |
01:37 ET | 250 | 1.015 |
02:22 ET | 150 | 1.015 |
02:38 ET | 1000 | 1.015 |
02:51 ET | 106 | 1.016 |
03:02 ET | 134 | 1.0111 |
03:07 ET | 2264 | 1.015 |
03:14 ET | 1000 | 1.0107 |
03:18 ET | 3000 | 1.0105 |
03:23 ET | 600 | 1.0171 |
03:25 ET | 100 | 1.015 |
03:27 ET | 2025 | 1.0125 |
03:36 ET | 525 | 1.017023 |
03:38 ET | 2712 | 1.01 |
03:41 ET | 18015 | 1.02 |
03:48 ET | 700 | 1.0118 |
03:54 ET | 130 | 1.0108 |
03:59 ET | 521 | 1.01 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Tiziana Life Sciences Ltd | 107.2M | -5.9x | --- |
Annovis Bio Inc | 107.6M | -1.8x | --- |
Verastem Inc | 105.0M | -0.8x | --- |
Fibrobiologics Inc | 110.4M | -3.4x | --- |
INmune Bio Inc | 110.0M | -2.5x | --- |
X4 Pharmaceuticals Inc | 111.2M | 7.6x | --- |
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $107.2M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 103.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.44 |
EPS | $-0.17 |
Book Value | $0.05 |
P/E Ratio | -5.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.